EMED Alleges RMS's HIgH-Flo™ Sets Infringe EMED's Newly Issued Patent in a Lawsuit Filed Yesterday
EMED Technologies today announced that it has filed a patent infringement lawsuit against Repro-Med Systems, Inc. (d/b/a RMS Medical Products) alleging that RMS's HIgH-Flo Subcutaneous Safety Needle Sets™ infringe the claims of EMED's newly issued patent.
On November 8, 2017, the U.S. Patent and Trademark Office issued U.S. Patent No. 9,808,576, a new patent that complements EMED's needle securement intellectual property portfolio. The invention disclosed and claimed in the '576 patent allows for the safe removal of needle infusion sets from patients and their safe disposal by sheathing the needle within a protective pair of folding wings during and after removal from the patient's skin.
The lawsuit was filed in the United States District Court for the Eastern District of Texas under case number 2:17-cv-00728.
The action is the latest step in EMED's continued enforcement of its safety-needle patent portfolio and reinforces the Company's commitment to protecting innovations that improve patient safety and clinical outcomes.
For more information about EMED's full portfolio of infusion solutions and patents, visit emedtc.com and emedtc.com/patents.
About EMED
EMED Technologies is an industry leader in the design, manufacture, and distribution of cutting-edge medical devices. For two decades, EMED Technologies has worked with clinicians, inventors, and medical companies to develop innovative medical products. Today, we are proud that both patients and clinicians can benefit from the fruits of our labor because we offer a wide variety of products and services that improve therapies and enhance clinical benefits. With our dynamic team of professionals, EMED continues to work with clinicians to understand their requirements and improve upon available technologies. In addition to novel technology, EMED is proud to offer licensing agreements for patented and proprietary technologies.
Media contact
For media inquiries, please contact info@emedtc.com.
Original release
The full press release is available on PR Newswire.